Despite accounting for 12.6% of global GLP-1 clinical trial activity in 2025, placing it third globally behind the US and China, prescribing rates for obesity indications remain comparatively low
By contrast, genuinely licensed weight-loss options are available, including the recently approved Wegovy pill (oral semaglutide)
A physician reviewed our intake and approved us two days after submission, sending the prescription details, treatment instructions, and support information through both email and a portal message
A transformation that begins with biology is now cascading across categories once siloed from healthcare, potentially blurring the lines between industries like food, wellness, beauty, retail, and travel